Australia’s first cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy is now reimbursed via the PBS. …
First in class therapy for obstructive hypertrophic cardiomyopathy now reimbursed
May 1, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News -
Industry alarm over the sudden pursuit of surprise uncertified claims
May 20, 2025 - - Latest News -
Medicines Australia sharpens post-election language on reform
May 20, 2025 - - Latest News -
Report highlights international confidence in Australian clinical trials
May 19, 2025 - - Latest News